WO2005029082A3 - Methods for the in vitro diagnosis and in vitro prognosis of cancer of the pancreas and for the development of drugs against cancer of the pancreas and/or pancreatitis - Google Patents

Methods for the in vitro diagnosis and in vitro prognosis of cancer of the pancreas and for the development of drugs against cancer of the pancreas and/or pancreatitis Download PDF

Info

Publication number
WO2005029082A3
WO2005029082A3 PCT/EP2004/010841 EP2004010841W WO2005029082A3 WO 2005029082 A3 WO2005029082 A3 WO 2005029082A3 EP 2004010841 W EP2004010841 W EP 2004010841W WO 2005029082 A3 WO2005029082 A3 WO 2005029082A3
Authority
WO
WIPO (PCT)
Prior art keywords
pancreas
cancer
vitro
pancreatitis
development
Prior art date
Application number
PCT/EP2004/010841
Other languages
French (fr)
Other versions
WO2005029082A2 (en
Inventor
Amo Iribarren Jokin Del
Sanchez-Vallejo Corin Junquera
Garay Jorge Ochoa
Garcia De Galdeano Pe Escudero
Sanchez Maria Eladi Argueelles
Los Toyos Gonzalez Juan Ram De
Cruz Simon Santa
Martinez Antonio Martinez
Serra Luis Barneo
Lopez De Castro Usue Ariz
Buela Laureano Simon
Original Assignee
Progenika Biopharma Sa
Amo Iribarren Jokin Del
Sanchez-Vallejo Corin Junquera
Garay Jorge Ochoa
Garcia De Galdeano Pe Escudero
Sanchez Maria Eladi Argueelles
Los Toyos Gonzalez Juan Ram De
Cruz Simon Santa
Martinez Antonio Martinez
Serra Luis Barneo
Lopez De Castro Usue Ariz
Buela Laureano Simon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenika Biopharma Sa, Amo Iribarren Jokin Del, Sanchez-Vallejo Corin Junquera, Garay Jorge Ochoa, Garcia De Galdeano Pe Escudero, Sanchez Maria Eladi Argueelles, Los Toyos Gonzalez Juan Ram De, Cruz Simon Santa, Martinez Antonio Martinez, Serra Luis Barneo, Lopez De Castro Usue Ariz, Buela Laureano Simon filed Critical Progenika Biopharma Sa
Publication of WO2005029082A2 publication Critical patent/WO2005029082A2/en
Publication of WO2005029082A3 publication Critical patent/WO2005029082A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/067—Pancreatitis or colitis

Abstract

The present invention refers to an in vitro method to detect pancreatic ductal adenocarcinoma and/or pancreatitis in an individual, to determine the stage or severity of said conditions in an individual, or to monitor the effect of therapy administeied to an individual with either one or both of said conditions; to screen for, identify, develop and evaluate the efficacy of compounds for the treatment of said conditions of the pancreas aimed at developing new medicinal products, as well as agents that inhibit the expression and/or activity of the DRM protein and/or the NBL1 protein, and/or the effects of said expression.
PCT/EP2004/010841 2003-09-24 2004-09-24 Methods for the in vitro diagnosis and in vitro prognosis of cancer of the pancreas and for the development of drugs against cancer of the pancreas and/or pancreatitis WO2005029082A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200302213A ES2303390B1 (en) 2003-09-24 2003-09-24 METHODS FOR IN VITRO AND IN VITRO DIAGNOSIS OF THE DUCTAL PANCREAS ADENOCARCINOMA AND / OR OF A PANCREATITIS; AND FOR THE DEVELOPMENT OF PHARMACS AGAINST DUCTAL PANCREAS ADENOCARCINOMA AND / OR AGAINST A PANCREATITIS.
ES200302213 2003-09-24

Publications (2)

Publication Number Publication Date
WO2005029082A2 WO2005029082A2 (en) 2005-03-31
WO2005029082A3 true WO2005029082A3 (en) 2005-09-22

Family

ID=34354858

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/010841 WO2005029082A2 (en) 2003-09-24 2004-09-24 Methods for the in vitro diagnosis and in vitro prognosis of cancer of the pancreas and for the development of drugs against cancer of the pancreas and/or pancreatitis

Country Status (2)

Country Link
ES (1) ES2303390B1 (en)
WO (1) WO2005029082A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007013360A2 (en) * 2005-07-27 2007-02-01 Oncotherapy Science, Inc. Pancreatic cancer related gene cst6 and gabrp
CN104321342B (en) * 2012-03-15 2017-12-22 首尔大学校产学协力团 The antibody of Gremlin 1
RU2714595C1 (en) * 2018-11-27 2020-02-18 Виктория Викторовна Абрамян Method for differential diagnosis of pancreatic cancer and chronic pancreatitis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999049041A1 (en) * 1998-03-26 1999-09-30 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Drm, a secreted protein with cell growth inhibiting activity, and related methods and compositions
US20010055785A1 (en) * 1997-04-10 2001-12-27 Charles Gilvarg Method of detecting procarboxypeptidase A and carboxypeptidase A levels in biological fluids
US6432410B1 (en) * 1997-02-05 2002-08-13 The Regents Of The University Of California Morphogenic proteins
US20020150894A1 (en) * 2000-12-08 2002-10-17 Batra Surinder K. Specific mucin expression as a marker for pancreatic cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001051628A2 (en) * 2000-01-14 2001-07-19 Millennium Pharmaceuticals, Inc. Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432410B1 (en) * 1997-02-05 2002-08-13 The Regents Of The University Of California Morphogenic proteins
US20010055785A1 (en) * 1997-04-10 2001-12-27 Charles Gilvarg Method of detecting procarboxypeptidase A and carboxypeptidase A levels in biological fluids
WO1999049041A1 (en) * 1998-03-26 1999-09-30 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Drm, a secreted protein with cell growth inhibiting activity, and related methods and compositions
US20020150894A1 (en) * 2000-12-08 2002-10-17 Batra Surinder K. Specific mucin expression as a marker for pancreatic cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HSU D R ET AL: "The Xenopus dorsalizing factor gremlin identifies a novel family of secreted proteins that antagonize BMP activities", MOLECULAR CELL, CAMBRIDGE, MA, US, vol. 1, April 1988 (1988-04-01), pages 673 - 683, XP002066230, ISSN: 1097-2765 *
IACOBUZIO-DONAHUE ET AL: "Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays", AMERICAN JOURNAL OF PATHOLOGY, PHILADELPHIA, PA, US, vol. 162, no. 4, April 2003 (2003-04-01), pages 1151 - 1162, XP009027111, ISSN: 0002-9440 *
TOPOL L Z ET AL: "IDENTIFICATION OF DRM, A NOVEL GENE WHOSE EXPRESSION IS SUPPRESSED IN TRANSFORMED CELLS AND WHICH CAN INHIBIT GROWTH OF NORMAL BUT NOT TRANSFORMED CELLS IN CULTURE", MOLECULAR AND CELLULAR BIOLOGY, WASHINGTON, DC, US, vol. 17, no. 8, August 1997 (1997-08-01), pages 4801 - 4810, XP002066577, ISSN: 0270-7306 *

Also Published As

Publication number Publication date
ES2303390B1 (en) 2009-08-17
ES2303390A1 (en) 2008-08-01
WO2005029082A2 (en) 2005-03-31

Similar Documents

Publication Publication Date Title
Arkenau et al. Targeting BRAF for patients with melanoma
Li et al. Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities
SG146653A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
WO2007103373A3 (en) Compositions and methods for the treatment of immunoinflammatory disorders
WO2007113648A3 (en) Ctla4 antibody combination therapy
WO2007112330A8 (en) Compositions and methods for detection, prognosis and treatment of colon cancer
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
BRPI0810336A2 (en) "method for treating and / or preventing skin ulcers in an individual"
WO2007141280A3 (en) Proteins
WO2003087831A3 (en) Proteins involved in breast cancer
ATE454465T1 (en) IN VITRO METHOD FOR IDENTIFYING COMPOUNDS FOR CANCER THERAPY
WO2008002611A3 (en) Delta-tocotrienol treatment and prevention of pancreatic cancer
EP1744162A4 (en) Cancer diagnosis and treatment using anti-robo1 antibody
Waldeck et al. Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH‐MYCN neuroblastoma mouse model
WO2003070700A3 (en) Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
TW200740441A (en) Methods and reagents for the treatment of inflammatory disorders
Lee et al. Management of cancer pain: 1. Wider implications of orthodox analgesics
WO2007047205A8 (en) Enzyme inhibitors of pai-1
Krueger et al. Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy
Ventura et al. hMTH1 expression protects mitochondria from Huntington's disease-like impairment
de Campos et al. Riluzole-induced recurrent pancreatitis
Lee et al. Hear and now: Ongoing clinical trials to prevent drug-induced hearing loss
Gastrup et al. Paracetamol decreases steady‐state exposure to lamotrigine by induction of glucuronidation in healthy subjects
SG148186A1 (en) Methods and reagents for the treatment of inflammatory disorders
WO2004003514A3 (en) Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase